A potent, reasonably selective Chk1 inhibitor with cell IC50 of 5 nM.

A potent, selective and orally active Chk1 inhibitor.

A potent, selective inhibitor of human LIMK1 with IC50 of 38 nM .

A potent, selective PLK1 PBD inhibitor with IC50 of 1.36 uM.

A potent, selective, ATP-competitive Chk1 and Chk2 inhibitor with IC50 of 4.4 nM and 4.5 nM, respectively.

A potent, selective, ATP-competitive Chk1 inhibitor with IC50 of 13.3 nM.

A potent, selective, orally active Mps1 (TTK) inhibitor with IC50 of 3.1 nM.

A potent, selective, orally bioavailable Mps1 kinase inhibitor with IC50 of 11 nM.

A potent, selective, reversible, ATP-competitive Chk2 inhibitor with IC50 of 0.2 uM.

A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.

A small-molecule inhibitor that blocks the Aurora C/IκBα interaction (IC50=24.9 uM) and exerts antitumor activity in MDA-MB-231 breast cancer cells.

A12B4C3 (hPNKP inhibitor A12B4C3) is a specific, noncompetitive inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase (hPNKP) with C50 of 60 nM, displays no inhibition of calcineurin and protein phosphatase-1 or APTX.

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides.

AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models. The no-adverse-effect dose of AG-024322 was 2 mg/kg and associated with ov

Alsterpaullone is a potent ATP-competitive and cell cycle cyclin-dependent kinase inhibitor, that is reported to be the most active Paullone.

AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM; >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2.

AMG 925 is a potent and selective dual inhibtor of CDK4/FLT3 with IC50s of 1.5 nM and 2.4 nM for CDK4 and FLT3, respectively; with IC50 of 19 nM in MOLM-13 cell.

Amonafide(AS1413) produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage.

amsilarotene (TAC-101) is a retinobenzoic acid with potential antineoplastic activity. TAC-101 inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest. This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).For the detailed information of TAC-101, the solubility of TAC-101 in water, the solubility of TAC-101 in DMSO, the solubility of TAC-101 in PBS buffer, the animal experiment (test) of TAC-101, the cell expriment (test) of TAC-101, the in vivo, in vitro and clinical trial test of TAC-101, the EC50, IC50,and Affinity of TAC-101, Please contact DC Chemicals..

AOH1160 is a potent, first-in-class, orally available small molecule inhibitor of Proliferating cell nuclear antigen (PCNA).